Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07709520
PHASE2

Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

Sponsor: Fujian Akeylink Biotechnology Co., Ltd.

View on ClinicalTrials.gov

Summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B

Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of GST-HG131/ GST-HG141 Tablets in Patients With Chronic Hepatitis B

Key Details

Gender

All

Age Range

35 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-07-10

Completion Date

2026-12-01

Last Updated

2026-07-16

Healthy Volunteers

No

Interventions

DRUG

GST-HG141

GST-HG141 is a novel, potent and selective HBV CAM, which has a distinct molecular mechanism of its antiviral action compared to other CAMs reported in the literature, and has demonstrated strong antiviral properties in pre-clinical studies in vitro and in vivo.

DRUG

GST-HG131

GST-HG131 is a novel dihydroquinolizinone (DHQ) compound, has been shown to reduce circulating levels of HBsAg in animals.

DRUG

GST-HG141 Placebo

GST-HG141 Placebo

Locations (1)

Beijing Friendship Hospital, Capital Medical University

Beijing, China